Sun Pharmaceuticals Industries Limited v. Emcure Pharmaceuticals Limited

In the high-stakes world of pharmaceuticals, a single syllable can be worth millions. When two drug makers stake their reputation on names that sound alike, the courtroom becomes the ultimate battleground for brand identity. This case between two of India's pharmaceutical heavyweights reveals a hard truth: being first to market does not guarantee you win the trademark war. The real question is whether the ear can tell the two marks apart.

Sun Pharmaceuticals Industries, the established player, built its brand around the trademark 'SUSTEN'. Emcure Pharmaceuticals Limited later entered the arena with its own mark, 'SUSTINEX'. Believing that Emcure had copied the core of its brand, Sun Pharmaceuticals filed a suit alleging trademark infringement and passing off. As the prior user of a similar-sounding mark, Sun Pharma sought to block Emcure from operating under 'SUSTINEX'. The dispute landed before the Bombay High Court, where the notice of motion became the focal point of the legal showdown.

Sun Pharmaceuticals argued that 'SUSTINEX' was deceptively similar to its registered 'SUSTEN' mark, contending that the shared prefix would confuse doctors, pharmacists, and patients into believing the two products came from the same source. The plaintiff leaned heavily on its status as the prior user, asserting that Emcure had deliberately ridden on the goodwill Sun Pharma had cultivated. Emcure countered that the marks were phonetically and visually distinct, pointing to the additional syllables and the clear audible divide that separated 'SUSTEN' from 'SUSTINEX'. The core legal friction centered on a single question: does a shared prefix automatically translate into deceptive similarity, or does the suffix carry enough weight to break the confusion?

The Bombay High Court ruled in favor of Emcure Pharmaceuticals, dismissing Sun Pharma's notice of motion. The court found that 'SUSTINEX' was not deceptively similar to 'SUSTEN', placing significant weight on phonetic distinctiveness. The judges noted a clear audible divide within 'SUSTINEX' that distinguished it from the plaintiff's mark when spoken aloud. Even though Sun Pharma was the prior user, the court held that this factor alone could not override the structural and phonetic differences between the two trademarks. The outcome meant Emcure could continue to operate under 'SUSTINEX' without legal restriction from this suit.

For founders and IP professionals, this case delivers a sharp lesson: prior use matters, but it is not a silver bullet. When evaluating trademark conflicts, courts look at the marks as a whole, weighing both phonetic and visual similarity holistically. A distinct suffix like 'NEX' can be enough to break the chain of deception, even when the prefix mirrors a competitor's brand. Before launching a new mark, invest in a thorough phonetic and visual clearance search, and remember that in trademark law, how a name sounds to a hurried customer can matter more than who used it first.